ArticleSurgery today2026
Outcomes of conversion surgery for patients with locally advanced pancreatic cancer under strict indication criteria.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeConversion surgery (CS) is performed for locally advanced pancreatic cancer (LAPC); however, the criteria for CS varies among institutions. This study aimed to evaluate the clinical outcomes of CS for LAPC based on strict indications at our center.
methodsThis study included patients diagnosed with and treated for LAPC between 2011 and 2021. The CS criteria indicated that the tumors shrunk to the same status as resectable pancreatic cancer (RPC) on imaging and were maintained for > 3 months. Additionally, tumors that had shrunk to a size corresponding to borderline resectable pancreatic cancer (BRPC) were observed on CT.
resultsTwenty-two patients underwent CS with a morbidity rate of 40.9% and no mortality. Overall survival after surgery in the LAPC group tended better than that in the BR and R groups (MST, LAPC, 59.7 months; BR, 38.6 months; R, 39.1 months; LAPC vs. BR, p = 0.085, vs. R, p = 0.065). Disease-free survival was similar across all resectability statuses: LAPC, 21.1 months; BR, 16.6 months; and R, 19.6 months (LAPC vs. BR, p = 1.000, vs. R, p = 1.000).
conclusionCS in patients with LAPC under strict criteria showed promising outcomes, demonstrating the potential benefit of this approach in carefully selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.